Patents by Inventor Evan Newell
Evan Newell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20250003973Abstract: The present disclosure provides methods for detecting antigen-specific cells, such as T cells or B cells, using a proximity ligation assay (PLA) in which at least one of the PLA probes is a peptide-major histocompatibility (MHC) multimer or a B cell specific antigen bound to an oligonucleotide. Also provided are kits for use in such methods.Type: ApplicationFiled: December 7, 2022Publication date: January 2, 2025Applicants: Fred Hutchinson Cancer Center, ImmunoScape Pte. Ltd.Inventors: Evan Newell, Zilei Liu
-
Publication number: 20230226135Abstract: The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods.Type: ApplicationFiled: July 16, 2020Publication date: July 20, 2023Applicant: BCell Solutions, Inc.Inventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20220265755Abstract: The invention relates to methods for modulating the neurological and immune function through targeting of acetylcholine (ACh) and CLIP. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including psychiatric or neurological disease, autoimmune disease, transplant and cell graft rejection, chronic wounds, non-neuronal immune disorders, Alzheimer's, Parkinson's Disease, Lewy Body dementia, pediatric acute neuropsychiatric syndromes (PANS), hypertension, late stage Ebola, Hantavirus, or coronavirus-induced hyperinflammatory conditions, including infections that cause a pathological “cytokine storm”, other post-infectious syndromes that result in cytokine storms in some people, and cancer, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject and improving cognition and addiction cessation methods.Type: ApplicationFiled: July 16, 2020Publication date: August 25, 2022Applicant: BCell Solutions, Inc.Inventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20200069766Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: August 19, 2019Publication date: March 5, 2020Applicant: The Regents of the University of Colorado, a Body CorporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Patent number: 10420813Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: GrantFiled: August 10, 2016Date of Patent: September 24, 2019Assignee: The Regents of the University of Colorado, a Body CorporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Publication number: 20170348377Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: August 10, 2016Publication date: December 7, 2017Applicant: Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Patent number: 9359404Abstract: The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure.Type: GrantFiled: November 30, 2012Date of Patent: June 7, 2016Assignees: Scott & White Healthcare, The Texas A&M University System, VG Life Sciences, Inc.Inventors: Martha Karen Newell-Rogers, Brett Mitchell, Evan Newell
-
Publication number: 20150231195Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: January 29, 2015Publication date: August 20, 2015Applicant: Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell-Rogers, Evan Newell
-
Patent number: 8957031Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: GrantFiled: October 23, 2008Date of Patent: February 17, 2015Assignee: Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell, Evan Newell
-
Publication number: 20140315818Abstract: The invention relates to methods for altering biological parameters in a subject, such as reducing blood pressure in a subject, by displacing CLIP, using a CLIP inhibitor. The methods are useful for treating disorders such as preeclampsia and high blood pressure.Type: ApplicationFiled: November 30, 2012Publication date: October 23, 2014Inventors: Martha Karen Newell, Brett Mitchell, Evan Newell
-
Patent number: 8557764Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules as well as gamma delta T cells. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS, as well as novel methods of diagnosis and of introducing a treatment regimen into a subject.Type: GrantFiled: January 28, 2008Date of Patent: October 15, 2013Assignee: The Regents of the University of Colorado, a body corporateInventors: Martha Karen Newell, Evan Newell
-
Publication number: 20130259829Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS.Type: ApplicationFiled: June 6, 2013Publication date: October 3, 2013Applicant: Viral Genetics, Inc.Inventors: Martha Karen Newell, Evan Newell, Haig Keledjian, Michael Agadjanyan
-
Patent number: 8329753Abstract: Methods and compositions for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using combination of compounds, or a bifunctional compound, that inhibits both fatty acid metabolism and glycolysis. In particular, the invention combines or links a glycolysis inhibitor that is, or that is derived from, hypoglycin A (also referred to as hypoglycine A) and a fatty acid metabolism inhibitor. Preferably, the invention provides bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a hypoglycin A derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of hypoglycin A.Type: GrantFiled: April 20, 2006Date of Patent: December 11, 2012Assignee: The Regents of the University of ColoradoInventors: Martha Karen Newell, Evan Newell
-
Patent number: 8293240Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a UCP and/or Fas antibody or other inhibitor, or combination thereof, and a therapeutically acceptable amount of a fatty acid metabolism inhibitor and/or a therapeutically acceptable amount of a glucose metabolism inhibitor, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an antibody against UCP and/or Fas antigen with an oxirane carboxylic acid, represented by etomoxir, and/or with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: GrantFiled: February 23, 2009Date of Patent: October 23, 2012Assignee: The Regents of the University of ColoradoInventors: Martha Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Publication number: 20120128724Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherapeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: ApplicationFiled: November 22, 2011Publication date: May 24, 2012Applicant: The Regents of the University of Colorado, a body corporateInventors: M. Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Patent number: 8071645Abstract: Systems and methods for treating inflammatory and proliferative diseases, and wounds, using as a pharmacon a fatty acid metabolism inhibitor, a glycolytic inhibitor, and/or an agent able to alter cellular production of reactive oxygen, or combination thereof, optionally in combination with one or more chemotherpeutic agents. In preferred embodiments, the invention combines an oxirane carboxylic acid, represented by etomoxir, with a 2-deoxyglucose compound, represented by 2-deoxy-D-glucose, and/or an antibody against UCP and/or Fas antigen. The systems and methods of the invention can be used to treat drug-resistant or multi-drug resistant cancers.Type: GrantFiled: June 11, 2004Date of Patent: December 6, 2011Assignee: The Regents of the University of ColoradoInventors: M. Karen Newell, Evan Newell, Elizabeth Villalobos-Menuey
-
Publication number: 20110118175Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, cancer, Alzheimer's disease, allergic disease, transplant and cell graft rejection, HIV infection and other viral, bacterial, and parasitic infection, and AIDS. Methods are also provided for preparing a peptide having the property of being able to displace CLIP by feeding one or more peptide sequences into software that predicts MHC Class II binding regions in an antigen sequence and related products.Type: ApplicationFiled: October 23, 2008Publication date: May 19, 2011Inventors: Martha Karen Newell, Evan Newell
-
Publication number: 20110015262Abstract: Methods and compositions for treating inflammatory and proliferative diseases, enabling treatment of MDR tumor cells by using combination of compounds, or a bifunctional compound, that inhibits both fatty acid metabolism and glycolysis. In particular, the invention combines or links a glycolysis inhibitor that is, or that is derived from, hypoglycin A (also referred to as hypoglycine A) and a fatty acid metabolism inhibitor. Preferably, the invention provides bifunctional compounds that link a moiety having the functionality of an oxirane carboxylic acid compound to a moiety having the functionality a hypoglycin A derivative. In specific embodiments, the invention provides a bifunctional compound that links a moiety having the functionality of etomoxir to a moiety having the functionality of hypoglycin A.Type: ApplicationFiled: April 20, 2006Publication date: January 20, 2011Inventors: Martha Karen Newell, Evan Newell
-
Publication number: 20100166789Abstract: The present invention describes compositions of thymus derived peptides and uses therefore in diagnostic methods and for the treatment of diseases associated with reduced T helper cell counts, diseases such as infection, e.g., HIV infection and other viral infections, parasitic, and bacterial infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, rheumatoid arthritis, Alzheimer's disease, asthma, allergy, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease/irritable bowel syndrome, Crohn's disease, Psoriasis, Chronic obstructive pulmonary disease, Systemic lupus erythematosus, transplant rejection and cancer.Type: ApplicationFiled: July 23, 2009Publication date: July 1, 2010Applicants: The Regents of the University of Colorado, Viral Genetics, Inc.Inventors: Haig Keledjian, Michael Agadjanyan, Martha Karen Newell, Evan Newell
-
Publication number: 20100166782Abstract: The invention relates to methods for modulating the immune function through targeting of CLIP molecules. The result is wide range of new therapeutic regimens for treating, inhibiting the development of, or otherwise dealing with, a multitude of illnesses and conditions, including autoimmune disease, allergic disease transplant and cell graft rejection, cancer, bacterial infection, HIV infection, and AIDS.Type: ApplicationFiled: July 23, 2009Publication date: July 1, 2010Inventors: Martha Karen Newell, Evan Newell, Haig Keledjian, Michael Agadjanyan